Drug Profile
MGD 1509
Alternative Names: GW5074/Sorafenib; MG O 1509; MG-D-1509; MG005/Sorafenib; Sorafenib/GW5074; Sorafenib/MG005Latest Information Update: 01 Jun 2022
Price :
$50
*
At a glance
- Originator Metagone Biotech; The General Hospital of the Three Armies
- Class Amides; Antineoplastics; Benzenesulfonates; Chlorobenzenes; Pyridines; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Death-associated protein kinase modulators; Fms-like tyrosine kinase 3 inhibitors; Mitogen-activated protein kinase inhibitors; Mitogen-activated protein kinase kinase inhibitors; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein b raf inhibitors; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Proto oncogene proteins c raf inhibitors; Raf kinase inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 08 Apr 2022 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 17 Mar 2021 MGD 1509 is still in phase I/II trial in Taiwan (Metagone Biotech pipeline, March 2021)
- 24 Jul 2020 Metagone Biotech completes a phase I/IIa trial in Solid tumour (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Taiwan (PO) (NCT03406364)